文献速递湿疹皮炎与荨麻疹

dupilumab治疗特应性皮炎的长期疗效与安全性:TREAT NL登记研究结果

Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
PubMed 文献 · J Am Acad Dermatol · 2020-05-30

TREAT NL是一项前瞻性观察性队列研究,纳入221例在常规临床中起始dupilumab治疗的特应性皮炎患者,其中103例基线使用系统治疗。至84周,EASI变化-15.2(SE 1.7),POEM变化-16.9(SE 1.4),DLQI变化-17.2(SE 1.6),IGA与瘙痒NRS呈随时间改善趋势。69例报告严重(含11例 Serious)不良事件,眼主诉最常见(46例),14例停药(主要因无效7例)。结论:dupilumab长达84周一般耐受良好(除外眼主诉),可视为长期有效治疗。

要点

  • dupilumab治疗84周可显著改善特应性皮炎体征、症状与生活质量
  • 眼主诉是最常见报告的不良事件,需关注眼部症状监测
  • 14例停药,主要因无效(7例),长期需评估疗效并及时调整方案

核心结论

  • 日常实践dupilumab治疗至84周一般耐受良好,除眼主诉外,可视为特应性皮炎的长期有效治疗。
  • 与局部治疗及初始联合系统治疗联用,可持续改善体征、症状与生活质量。

研究设计与样本

  • 前瞻性观察性队列研究,纳入221例在常规临床中起始dupilumab的特应性皮炎患者,其中103例基线使用系统治疗。
  • 研究评估长达84周的dupilumab治疗的患者特征、治疗方面、疗效与安全性。

主要发现

  • 84周时EASI变化-15.2(SE 1.7),POEM变化-16.9(SE 1.4),DLQI变化-17.2(SE 1.6)。
  • IGA与瘙痒NRS呈随时间改善趋势。
  • 69例患者观察到严重不良事件(n=79)包括Serious不良事件(n=11)。
  • 眼主诉报告最多(n=46)。
  • 21例调整常规给药方案,14例停药,主要因无效(n=7)。

临床怎么用

  • dupilumab可用于特应性皮炎的长期治疗,需联合局部治疗及初始系统治疗。
  • 治疗中应监测眼部主诉,关注严重不良事件。
  • 长期治疗需评估疗效,无效者(如7例停药)需考虑调整方案。

局限性

  • 出于可行性原因,仅登记严重和Serious不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence on long-term dupilumab treatment for atopic dermatitis in daily practice is lacking. OBJECTIVE: To investigate patient characteristics, treatment aspects, effectiveness, and safety of up to 84 weeks of dupilumab treatment. METHODS: An observational prospective cohort study was conducted of patients with atopic dermatitis starting dupilumab in routine clinical care. RESULTS: Of the 221 included patients, 103 used systemic therapy at baseline. At 84 weeks, we found a change of -15.2 (SE, 1.7) for the Eczema Area and Severity Index, -16.9 (SE, 1.4) for the Patient-Oriented Eczema Measure, and -17.2 (SE, 1.6) for the Dermatology Life Quality Index. We found a trend for improvement over time for the Investigator Global Assessment and Numerical Rating Scale for pruritus. Severe (n = 79) including serious (n = 11) adverse events were observed in 69 patients. Eye complaints were most frequently reported (n = 46). Twenty-one patients adjusted the regular dosing schedule, and 14 patients discontinued treatment, mainly due to ineffectiveness (n = 7). LIMITATIONS: Only adverse events of severe and serious nature were registered for feasibility reasons. CONCLUSION: Daily practice dupilumab treatment of up to 84 weeks is generally well-tolerated, apart from the reporting of eye complaints. It can be considered a long-term effective treatment for atopic dermatitis in combination with topical and initial concomitant systemic treatment, showing a sustained improvement of signs, symptoms, and quality of life.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Bosma AL, de Wijs LEM, Hof MH, et al. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. J Am Acad Dermatol. 2020. PMID: 32485210. doi:10.1016/j.jaad.2020.05.128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。